Sikkim Journal

DelveInsight’s “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the IgA Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; IgA Nephropathy Market Forecast

Some of the key facts of the IgA Nephropathy Market Report: 

• The IgA Nephropathy market size was valued approximately USD 113 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2024, Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company in the advanced stages of clinical development focused on innovative treatments for individuals with severe immunologic conditions, announced today the addition of two seasoned industry professionals to spearhead the advancement of the company’s drug initiatives. This includes their late-stage candidate, atacicept, presently undergoing a Phase 3 clinical trial for IgA nephropathy (IgAN). Effective immediately, Robert M. Brenner, M.D., assumes the role of Chief Medical Officer, succeeding Dr. Celia Lin, M.D., while William D. Turner takes on the position of Chief Development Officer.
• In June 2023, Chinook Therapeutics, Inc. has disclosed a merger agreement with Novartis AG, outlining Novartis’s acquisition of Chinook for $40 per share in cash, totaling $3.2 billion. This proposed offer reflects an 83% premium over Chinook’s 60-day volume-weighted average stock price and a 67% premium over Chinook’s closing price on June 9, 2023. Additionally, Chinook shareholders are set to receive contingent value rights (CVRs) allowing for payments of up to $4 per share based on the accomplishment of specific regulatory milestones for Chinook’s primary product candidate, atrasentan.
• In 2021, IgA nephropathy (IgAN) affected around 400,000 individuals across the 7MM (Seven Major Markets). Among these cases, the United States had the highest incidence, with roughly 135,000 cases, while Spain had the lowest, with approximately 20,000 cases.
• The epidemiology of IgA nephropathy (IgAN) is analyzed based on total prevalence, gender-specific occurrences, and age-specific cases. In the United States, there were more than 60,000 cases within the age bracket of 45–64 years, and this figure is anticipated to increase by 2032.
• In 2021, within the European Union’s four major markets (EU4) and the UK, Germany recorded the highest prevalence of IgA nephropathy (IgAN) with approximately 32,000 cases.
• Key IgA Nephropathy Companies: Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others
• Key IgA Nephropathy Therapies: Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others
• The IgA Nephropathy epidemiology based on gender analyzed that IgAN is more prominent in males in comparison to females. Prevalence of IgAN occurs in men around two times more than females worldwide.
• The IgA Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgA Nephropathy pipeline products will significantly revolutionize the IgA Nephropathy market dynamics.

IgA Nephropathy Overview

IgA nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the kidneys. This buildup can lead to inflammation and damage to the tiny filters in the kidneys called glomeruli. IgA nephropathy is one of the most common forms of glomerulonephritis, which is inflammation of the glomeruli.

Get a Free sample for the IgA Nephropathy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/iga-nephropathy-market

IgA Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

IgA Nephropathy Epidemiology Segmentation:

The IgA Nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of IgA Nephropathy
• Prevalent Cases of IgA Nephropathy by severity
• Gender-specific Prevalence of IgA Nephropathy
• Diagnosed Cases of Episodic and Chronic IgA Nephropathy

Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ IgA Nephropathy Epidemiology Forecast

IgA Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy market or expected to get launched during the study period. The analysis covers IgA Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the IgA Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

IgA Nephropathy Therapies and Key Companies

• Sibeprenlimab: Visterra
• Atrasentan: Chinook Therapeutics
• LNP023: Novartis Pharmaceuticals
• Research programme: IgA proteases Selecta Biosciences
• AP 305: Shanghai Alebund Pharmaceuticals
• ADR-001: Rohto Pharmaceutical
• MY 008: Wuhan Createrna Science and Technology
• SHR-2010: Guangdong Hengrui Pharmaceutical
• IONIS FB: LRx Ionis Pharmaceuticals
• HR19042: Jiangsu HengRui Medicine Co., Ltd.
• Sparsentan: Travere Therapeutics
• HR19042: Jiangsu HengRui Medicine Co., Ltd.

Discover more about therapies set to grab major IgA Nephropathy market share @ IgA Nephropathy Treatment Landscape

IgA Nephropathy Market Drivers

• Increase in prevalence of IgA Nephropathy (IgAN), increment in the number of government initiatives to spread awareness are some of the important factors that are fueling the IgA Nephropathy Market.

IgA Nephropathy Market Barriers

• However, lack of in-depth understanding of the disease pathogenesis, the unreported and undiagnosed IgA Nephropathy cases and other factors are creating obstacles in the IgA Nephropathy Market growth.

Scope of the IgA Nephropathy Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key IgA Nephropathy Companies: Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others
• Key IgA Nephropathy Therapies: Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others
• IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies
• IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• IgA Nephropathy Unmet Needs, KOL’s views, Analyst’s views, IgA Nephropathy Market Access and Reimbursement 

To know more about IgA Nephropathy companies working in the treatment market, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment

Table of Contents 

1. IgA Nephropathy Market Report Introduction

2. Executive Summary for IgA Nephropathy

3. SWOT analysis of IgA Nephropathy

4. IgA Nephropathy Patient Share (%) Overview at a Glance

5. IgA Nephropathy Market Overview at a Glance

6. IgA Nephropathy Disease Background and Overview

7. IgA Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of IgA Nephropathy 

9. IgA Nephropathy Current Treatment and Medical Practices

10. IgA Nephropathy Unmet Needs

11. IgA Nephropathy Emerging Therapies

12. IgA Nephropathy Market Outlook

13. Country-Wise IgA Nephropathy Market Analysis (2019–2032)

14. IgA Nephropathy Market Access and Reimbursement of Therapies

15. IgA Nephropathy Market Drivers

16. IgA Nephropathy Market Barriers

17.  IgA Nephropathy Appendix

18. IgA Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/